Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
This research trial studies deoxyribonucleic acid (DNA) in blood or bone marrow samples from younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.

Detailed Description
-----------------
PRIMARY OBJECTIVES: l. Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML) relapse and infection risk. II. Validate positive associations seen in the genome-wide scan with a fine mapping approach. III. Perform simulated clinical trials using germline genetic variation data to test the feasibility of using genetic data to inform the clinical care of pediatric patients with AML. OUTLINE: Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.

Official Title
-----------------
Genetic Predictors of AML Treatment Response

Conditions
-----------------
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission

Intervention / Treatment
-----------------
* Other: Laboratory Biomarker Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of AML In remission Adequate DNA from peripheral blood or bone marrow samples Concurrent enrollment on CCG-2961, COG-AAML03P1, COG-AAML0531, AML-93, AML-97, AML-04,AML-09, or Canada AML Infection clinical trial required

Ages Eligible for Study
-----------------
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-correlative (predictors of AML treatment outcomes)<br>Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications. | Other: Laboratory Biomarker Analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of first acute myeloid leukemia relapse |  | Up to 2 years | 
| Rate of invasive bacterial infections defined as the number of invasive infection episodes divided by the days at risk |  | From study entry date to completion of therapy date provided on the final Reporting Period case reporting form, assessed up to 2 years |